Sign inJoin waitlistJoin the waitlist

Harold Burstein

Director of Academic Partnerships · Mass General Brigham

Credentials: · · · ·

History

Breast Cancer Education · Mass General Brigham
Present
Breast Oncology · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
1997–2000
Internal Medicine
Massachusetts General Hospital
1994–1997
Harvard Medical School
1990–1994
Harvard University
1986–1990

Research

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer
Journal of Clinical Oncology · 2005 · 1,362 citations
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology · 2017 · Co-first of 55 authors · 848 citations
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2024 · 832 citations

Eric Winer
114 papers
CH
Clifford Hudis
38 papers
AW
Antonio Wolff
35 papers
Ann Partridge
34 papers · 3 as a fellow
Erica Mayer
34 papers · 4 as a fellow
Hope Rugo
32 papers
Sara Tolaney
30 papers · 2 as a fellow
William Gradishar
26 papers
PM
Paul Marcom
25 papers
LG
Lori Goldstein
24 papers
Sharon Giordano
22 papers
SI
Steven Isakoff
21 papers

Grants

NCTN Lead Academic Participating Site at Dana-Farber/Harvard Cancer Consortium
National Cancer Institute · UG1
Contact PI · $8.6M · Dana-Farber Cancer Inst
2019–2032
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
National Cancer Institute · U10
Contact PI · $6.2M · Dana-Farber Cancer Inst
2014–2019
Cancer and Leukemia Group B
National Cancer Institute · U10
Contact PI · $2.3M · Dana-Farber Cancer Inst
1982–2015

Clinical trials

Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Principal investigator · Completed · Phase 2
Harold J. Burstein, MD, PhD
2008–2012
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Principal investigator · Completed · Phase 3
National Cancer Institute (NCI)
2006–2014
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Principal investigator · Completed
Harold J. Burstein, MD, PhD
2006–2008
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2005–2007